Related Experiment Video
Updated: Jul 12, 2026
Visualizing Lymph Node Structure and Cellular Localization using Ex-Vivo Confocal Microscopy
Published on: August 9, 2019
Iosimenol, a new non-ionic dimeric contrast medium, does not induce immunoreactivity in the popliteal lymph node
M J Fernandez Cabezudo1, G Petroianu, B Al-Ramadi
1Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, PO Box 17666, Tawam Street, Al Ain, Abu Dhabi, UAE.
Insights
The new contrast medium iosimenol showed no immunological effects in mouse studies. This finding suggests iosimenol may be a safe option for high-risk patients needing contrast imaging.
Area of Science:
- Immunology
- Radiology
- Pharmacology
Background:
- Non-ionic dimeric contrast media (CM) are essential in medical imaging.
- Assessing the immunogenicity of new CM is crucial for patient safety.
- Iosimenol is a novel non-ionic dimeric CM requiring safety evaluation.
Purpose of the Study:
- To evaluate the potential immunoreactivity of the new contrast medium iosimenol.
- To compare the immunological profile of iosimenol with iodixanol.
- To determine the safety of iosimenol for clinical use, particularly in high-risk populations.
Main Methods:
- Animal studies were conducted using mice.
- Potential immunoreactivity was assessed using passive lymph node assay (PLNA) and flow cytometry.
- Streptozotocin (STZ) and vehicle injections served as positive and negative controls, respectively.
Main Results:
- No significant immunological effects were observed with iosimenol.
- Comparative analysis with iodixanol did not reveal differential immunoreactivity.
- Control groups showed expected responses, validating the study's methodology.
Conclusions:
- The new contrast medium iosimenol demonstrates a lack of immunogenicity in preclinical studies.
- Iosimenol presents a potentially safer alternative for contrast-enhanced imaging procedures.
- Further clinical investigation is warranted to confirm the safety and efficacy of iosimenol in high-risk patient groups.
Abstract:
Animal studies in mice were conducted to determine the potential immunoreactivity of the new non-ionic dimeric contrast medium (CM) iosimenol using the PLNA and flow cytometric analyses. Comparative studies were performed with iodixanol. The known immune-reactive substance strepozotocin (STZ) and vehicle injections served as positive and negative controls, respectively. Our experiments did not show any immunological effect of iosimenol, concluding that the new CM iosimenol may be beneficial for use in high-risk patients.
